Viatris' Mylan Wins Key Ruling in Teva Copaxone Antitrust Lawsuit
VTRS has more than doubled off its 52-week low of $6.85.
Summary
A New Jersey federal judge has ruled that Teva Pharmaceutical must face key antitrust claims brought by Viatris' Mylan subsidiary regarding its multiple sclerosis drug Copaxone. The judge denied Teva's motion to dismiss allegations that it unlawfully blocked generic competition by spreading false information and pressuring pharmacy benefit managers. This decision allows the lawsuit, filed in 2021, to proceed on material claims, increasing the potential for a significant financial outcome for Viatris. Copaxone generated over $4.2 billion for Teva in 2016, and the EU previously fined Teva over $500 million for similar anticompetitive practices. Traders will monitor the lawsuit's progression for potential settlement or trial developments.
At the time of this announcement, VTRS was trading at $13.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8B. The 52-week trading range was $6.85 to $16.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.